BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 33079969)

  • 1. Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study.
    McKeigue PM; Weir A; Bishop J; McGurnaghan SJ; Kennedy S; McAllister D; Robertson C; Wood R; Lone N; Murray J; Caparrotta TM; Smith-Palmer A; Goldberg D; McMenamin J; Ramsay C; Hutchinson S; Colhoun HM;
    PLoS Med; 2020 Oct; 17(10):e1003374. PubMed ID: 33079969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics Associated With Racial/Ethnic Disparities in COVID-19 Outcomes in an Academic Health Care System.
    Gu T; Mack JA; Salvatore M; Prabhu Sankar S; Valley TS; Singh K; Nallamothu BK; Kheterpal S; Lisabeth L; Fritsche LG; Mukherjee B
    JAMA Netw Open; 2020 Oct; 3(10):e2025197. PubMed ID: 33084902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10 131 US Veterans With SARS-CoV-2 Infection.
    Ioannou GN; Locke E; Green P; Berry K; O'Hare AM; Shah JA; Crothers K; Eastment MC; Dominitz JA; Fan VS
    JAMA Netw Open; 2020 Sep; 3(9):e2022310. PubMed ID: 32965502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
    Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
    Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.
    de Abajo FJ; Rodríguez-Martín S; Lerma V; Mejía-Abril G; Aguilar M; García-Luque A; Laredo L; Laosa O; Centeno-Soto GA; Ángeles Gálvez M; Puerro M; González-Rojano E; Pedraza L; de Pablo I; Abad-Santos F; Rodríguez-Mañas L; Gil M; Tobías A; Rodríguez-Miguel A; Rodríguez-Puyol D;
    Lancet; 2020 May; 395(10238):1705-1714. PubMed ID: 32416785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study.
    Petrilli CM; Jones SA; Yang J; Rajagopalan H; O'Donnell L; Chernyak Y; Tobin KA; Cerfolio RJ; Francois F; Horwitz LI
    BMJ; 2020 May; 369():m1966. PubMed ID: 32444366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis.
    Harrison SL; Fazio-Eynullayeva E; Lane DA; Underhill P; Lip GYH
    PLoS Med; 2020 Sep; 17(9):e1003321. PubMed ID: 32911500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Race and Ethnicity With Comorbidities and Survival Among Patients With COVID-19 at an Urban Medical Center in New York.
    Kabarriti R; Brodin NP; Maron MI; Guha C; Kalnicki S; Garg MK; Racine AD
    JAMA Netw Open; 2020 Sep; 3(9):e2019795. PubMed ID: 32975574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Deeks JJ; Dinnes J; Takwoingi Y; Davenport C; Spijker R; Taylor-Phillips S; Adriano A; Beese S; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Dittrich S; Emperador D; Hooft L; Leeflang MM; Van den Bruel A;
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013652. PubMed ID: 32584464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19, Australia: Epidemiology Report 17 (Fortnightly reporting period ending 24 May 2020).
    COVID-19 National Incident Room Surveillance Team
    Commun Dis Intell (2018); 2020 Jun; 44():. PubMed ID: 32517645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study.
    Webb GJ; Marjot T; Cook JA; Aloman C; Armstrong MJ; Brenner EJ; Catana MA; Cargill T; Dhanasekaran R; García-Juárez I; Hagström H; Kennedy JM; Marshall A; Masson S; Mercer CJ; Perumalswami PV; Ruiz I; Thaker S; Ufere NN; Barnes E; Barritt AS; Moon AM
    Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):1008-1016. PubMed ID: 32866433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial Disparities in Incidence and Outcomes Among Patients With COVID-19.
    Muñoz-Price LS; Nattinger AB; Rivera F; Hanson R; Gmehlin CG; Perez A; Singh S; Buchan BW; Ledeboer NA; Pezzin LE
    JAMA Netw Open; 2020 Sep; 3(9):e2021892. PubMed ID: 32975575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Underlying Comorbidities on the Infection and Severity of COVID-19 in Korea: a Nationwide Case-Control Study.
    Ji W; Huh K; Kang M; Hong J; Bae GH; Lee R; Na Y; Choi H; Gong SY; Choi YH; Ko KP; Im JS; Jung J
    J Korean Med Sci; 2020 Jun; 35(25):e237. PubMed ID: 32597048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study.
    Clark A; Jit M; Warren-Gash C; Guthrie B; Wang HHX; Mercer SW; Sanderson C; McKee M; Troeger C; Ong KL; Checchi F; Perel P; Joseph S; Gibbs HP; Banerjee A; Eggo RM;
    Lancet Glob Health; 2020 Aug; 8(8):e1003-e1017. PubMed ID: 32553130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study.
    Nikpouraghdam M; Jalali Farahani A; Alishiri G; Heydari S; Ebrahimnia M; Samadinia H; Sepandi M; Jafari NJ; Izadi M; Qazvini A; Dorostkar R; Tat M; Shahriary A; Farnoosh G; Hosseini Zijoud SR; Taghdir M; Alimohamadi Y; Abbaszadeh S; Gouvarchin Ghaleh HE; Bagheri M
    J Clin Virol; 2020 Jun; 127():104378. PubMed ID: 32353762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute kidney injury associated with COVID-19: A retrospective cohort study.
    Kolhe NV; Fluck RJ; Selby NM; Taal MW
    PLoS Med; 2020 Oct; 17(10):e1003406. PubMed ID: 33125416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.